Background

Epilepsy is a neurological disorder characterized by repeated convulsions and seizures due to abnormal hyperexcitability of brain neurons. While many patients manage symptoms with anticonvulsant drugs, approximately 30% of all patients suffer from drug-resistant epilepsy, where seizures are not controlled even with two or more medications. For patients who fail drug therapy, surgical options such as resection of the brain area where seizures originate or neurostimulation using electrical signals are proposed as alternatives.

These surgical approaches have clear limitations. If the epileptic focus is located in a critical functional area responsible for language, memory, or motor function, the brain tissue cannot be resected due to the high risk of losing normal brain function. Existing brain surgeries or electrode insertions carry the risk of irreversible neural damage, and neuromodulation devices have been evaluated as lacking sufficient responsiveness to completely suppress seizure occurrence itself. The development of precision control therapeutic technologies that selectively inhibit excitatory neurons in the lesion area while preserving normal brain tissue has remained a persistent challenge for the academic community.

Key Findings

A neurosurgery research team led by Yang Dai at Xuanwu Hospital in Beijing, China, has released early clinical results of treating drug-resistant epilepsy patients using chemogenetics technology, which combines modified viral vectors with orally administered drugs. The results of this study were published in the New England Journal of Medicine and attracted attention from the international academic community, including Nature News.

Three adult patients with drug-resistant epilepsy, whose seizures had not stopped despite existing drug treatments for 10 to 25 years, participated in the clinical trial. The researchers precisely micro-injected an engineered Adeno-Associated Virus (AAV) into the seizure-inducing area of the brain. The delivered AAV expresses engineered receptor genes designed to bind only to excitatory neurons. This receptor acts as a genetic switch that responds selectively to specific compounds rather than endogenous substances.

When low-dose clozapine was administered to the patients, the drug bound to the engineered receptors, rapidly calming the excessive electrical excitation of the neurons. This method works like a dimmer switch that regulates brain cell output, gently reducing neurotransmission. As a result of the treatment, the monthly average seizure frequency decreased by more than 90% in all three patients. The frequent seizures that had paralyzed daily life have almost disappeared, and no significant neurological deficits or serious adverse events occurred during the clinical observation period. It effectively suppressed hyperactivity in the neural network using only a precise biological switch and low-dose drug administration, without resecting existing brain tissue.

Significance and Outlook

This achievement is a first-of-its-kind result confirming the clinical validity of chemogenetics technology in the human central nervous system. It has opened a path to reversibly control neuronal activity without using a surgical scalpel to excise parts of the brain. In particular, the ability to finely adjust the intensity of inhibition by controlling the drug administration cycle and concentration is a strength that existing surgeries do not possess.

There are certainly hurdles to overcome before the commercialization of this treatment. As this is an early Phase 1 study with only three target patients, the sample size is too small to ensure statistical reliability. Long-term follow-up studies are needed to determine how long the delivered genes maintain expression in brain cells and whether resistance develops to the repeatedly administered regulatory drugs. The host immune response to the viral vector and the potential metabolic effects of trace amounts of drugs during long-term administration must also be closely verified. The subsequent research team faces the challenge of conducting randomized controlled trials on larger patient groups to demonstrate safety and reproducibility.